Planning interventional trials in childhood arterial ischaemic stroke using a Delphi consensus process.
Maja Steinlin, Finbar O'callaghan, Mark T Mackay
https://pubmed.ncbi.nlm.nih.gov/28121022/Actively Recruiting
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2025-11-18
70
Participants Needed
35
Research Sites
N/A
Total Duration
This trial focuses on children with focal cerebral arteriopathy FCA, a rare but serious condition that causes stroke in childhood. FCA is an inflammatory disease of the blood vessels in the brain triggered by infection. Researchers aim to find out if treating children with high dose steroids plus aspirin leads to better and faster recovery, improved clinical outcomes, and fewer stroke recurrences compared to treatment with aspirin alone. This is a phase 3, randomized controlled study conducted across multiple international centers. Participants will be randomly assigned to one of two groups one group will receive standard care including aspirin plus high dose intravenous methylprednisolone followed by oral prednisolone tapering, while the other group will receive standard care including aspirin without steroids. Steroid treatment is given intravenously for 3 days at 30 mgkgday maximum 1000 mgday, followed by oral prednisolone for 4 weeks with a tapering dose schedule. Treatment begins within 48 hours of diagnosis and no later than 96 hours after stroke onset. Children will be monitored at 1, 3, 6, and 12 months after treatment begins. Evaluations include neurological exams, MRI and MRA imaging at 1, 3 if available, and 6 months, and various outcome assessments such as stroke severity scores, functional measures, cognitive tests, and quality of life questionnaires. Researchers will track recovery, stroke recurrence, and vessel changes to assess treatment effects and safety over the study duration of 48 months.
CONDITIONS
High Dose Steroids in Children With Stroke
M
Maja Steinlin, Dr. med.
K
Kathrin Bochud, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Insel Gruppe AG, University Hospital Bern
Lead Sponsor
University of Bern
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 4 days
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for diagnosis and eligibility confirmation
Duration - 4 weeks
Participants receive either standard care including aspirin or standard care plus high dose steroids consisting of intravenous Methylprednisolone for 3 days followed by oral Prednisolone tapering over 4 weeks.
1 baseline visit and multiple follow-up visits at 1, 3, 6, and 12 months
Duration - Up to 12 months
Participants are monitored for recovery, functional outcomes, and stroke recurrence with clinical assessments and imaging at scheduled intervals.
Visits at 1, 3, 6, and 12 months including MRI/MRA imaging at 1, 3 (if available), and 6 months
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maja Steinlin, Finbar O'callaghan, Mark T Mackay
https://pubmed.ncbi.nlm.nih.gov/28121022/Heather J Fullerton, Nancy K Hills, Hui Chen...
https://pubmed.ncbi.nlm.nih.gov/40351190/Insel Gruppe AG, University Hospital Bern
Lead Sponsor
University of Bern
Collaborating Sponsor